Risks and limits of APOE Senioren

The APOE genotype, particularly the ε4 allele, is the strongest known genetic risk factor for late-onset sporadic Alzheimer's disease. However, its predictive value for individual seniors is limited: not all ε4 carriers develop dementia, and many non-carriers do. The risk increase is moderate (3- to 12-fold for homozygotes) and heavily modified by lifestyle, cardiovascular health, and education. For asymptomatic seniors, the test offers little clinical utility because no causal treatment exists. Risks include psychological distress (anxiety, stigma), false reassurance for ε2/ε3 carriers, potential insurance discrimination, and misinterpretation by consumers. Professional guidelines (e.g., German Society of Human Genetics) advise against predictive testing for incurable conditions without preventive options. Evidence: The association is robust (GWAS, meta-analyses), but clinical validity for asymptomatic seniors is weak. Conclusion: APOE testing in seniors is scientifically questionable and ethically sensitive; thorough counseling about limitations is mandatory.